As part of Stago's continuous improvement commitment, STA® -Liatest® D-Di Plus* was developed as an evolution of the STA® -Liatest® D-Di, on...
To fulfil regulatory requirements, laboratories must perform regular internal quality control (IQC) on at least two concentration levels (no...
Rivaroxaban is a new oral anticoagulant, direct factor Xa inhibitor, developed by Bayer HealthCare and sold under the trade name Xarelto®. ...
For every Heparin Induced Thrombocytopenia (HIT) suspicion. A rapid and specific exclusion of Heparin Induced Thrombocytopenia in 10 minute...
Stago is the market leader in the supply of Haemostasis products within the ANZ market.
Our ANZ head office and training facilities are located in Doncaster, and we have a presence in most states of Australia and both islands in New Zealand.
Our team is highly specialised, and able to support you in the field of Haemostasis.
Stago’s first mission is to provide health professionals with reliable, powerful and innovative haemostasis diagnostic tools in looking for a way to improve prevention, understanding, diagnostic, treatment and follow-up of coagulation-related pathologies.
October 28 - 31, 2012
August 20 - 23, 2013
Did you know?
In 1953, Dr R. Langdell et al. proposed a plasma clotting test that could be used for assaying antihaemophilic factor. They designated their one-stage test as "partial thromboplastin time".
Sorry, we don't have any job openings at the moment. Please check back later.